Furthermore, combined blockade of NRP-2 action and treatment with bevacizumab anti-angiogenic therapy produced synergistic inhibition of melanoma xenograft growth [36], a finding that has implications for GBM treatment given the emerging therapeutic role of bevacizumab in this disease [37]. This evidence concerns the gene NRP2 and melanoma.